HomeCompareCLVLY vs STAG

CLVLY vs STAG: Dividend Comparison 2026

CLVLY yields 0.36% · STAG yields 3.44%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CLVLY wins by $287.2K in total portfolio value
10 years
CLVLY
CLVLY
● Live price
0.36%
Share price
$7.24
Annual div
$0.03
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$305.5K
Annual income
$199,327.02
Full CLVLY calculator →
STAG
STAG Industrial Inc.
● Live price
3.44%
Share price
$36.06
Annual div
$1.24
5Y div CAGR
0.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$18.3K
Annual income
$462.70
Full STAG calculator →

Portfolio growth — CLVLY vs STAG

📍 CLVLY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCLVLYSTAG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CLVLY + STAG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CLVLY pays
STAG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CLVLY
Annual income on $10K today (after 15% tax)
$30.66/yr
After 10yr DRIP, annual income (after tax)
$169,427.97/yr
STAG
Annual income on $10K today (after 15% tax)
$292.69/yr
After 10yr DRIP, annual income (after tax)
$393.29/yr
At 15% tax rate, CLVLY beats the other by $169,034.67/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CLVLY + STAG for your $10,000?

CLVLY: 50%STAG: 50%
100% STAG50/50100% CLVLY
Portfolio after 10yr
$161.9K
Annual income
$99,894.86/yr
Blended yield
61.70%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on STAG right now

CLVLY
No analyst data
Altman Z
17.2
Piotroski
5/9
STAG
Analyst Ratings
9
Buy
9
Hold
3
Sell
Consensus: Buy
Price Target
$45.00
+24.8% upside vs current
Range: $39.00 — $59.00
Altman Z
1.2
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CLVLY buys
0
STAG buys
0
No recent congressional trades found for CLVLY or STAG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCLVLYSTAG
Forward yield0.36%3.44%
Annual dividend / share$0.03$1.24
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%0.3%
Portfolio after 10y$305.5K$18.3K
Annual income after 10y$199,327.02$462.70
Total dividends collected$276.6K$4.0K
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: CLVLY vs STAG ($10,000, DRIP)

YearCLVLY PortfolioCLVLY Income/yrSTAG PortfolioSTAG Income/yrGap
1← crossover$10,772$72.13$10,665$345.38+$107.00CLVLY
2$11,671$145.24$11,365$358.01+$306.00CLVLY
3$12,783$294.14$12,099$370.76+$684.00CLVLY
4$14,279$602.13$12,870$383.63+$1.4KCLVLY
5$16,536$1,257.27$13,678$396.60+$2.9KCLVLY
6$20,415$2,721.45$14,526$409.67+$5.9KCLVLY
7$28,124$6,280.07$15,413$422.82+$12.7KCLVLY
8$46,264$16,171.07$16,343$436.05+$29.9KCLVLY
9$99,224$49,721.74$17,315$449.35+$81.9KCLVLY
10$305,497$199,327.02$18,332$462.70+$287.2KCLVLY

CLVLY vs STAG: Complete Analysis 2026

CLVLYStock

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke increased and prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.

Full CLVLY Calculator →

STAGREIT

STAG Industrial, Inc. (NYSE: STAG) is a real estate investment trust focused on the acquisition and operation of single-tenant, industrial properties throughout the United States. By targeting this type of property, STAG has developed an investment strategy that helps investors find a powerful balance of income plus growth.

Full STAG Calculator →
📬

Get this CLVLY vs STAG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CLVLY vs SCHDCLVLY vs JEPICLVLY vs OCLVLY vs KOCLVLY vs MAINCLVLY vs PLDCLVLY vs EQRCLVLY vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.